Comparative Pharmacology
Head-to-head clinical analysis: LUPRON DEPOT PED KIT versus TRIPTODUR KIT.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LUPRON DEPOT PED KIT versus TRIPTODUR KIT.
LUPRON DEPOT-PED KIT vs TRIPTODUR KIT
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Leuprolide acetate, a GnRH agonist, initially stimulates pituitary gonadotropin release, but chronic administration suppresses LH and FSH secretion by downregulation of GnRH receptors, leading to reduced sex steroid production.
Gonadotropin-releasing hormone (GnRH) agonist; continuous administration suppresses pituitary gonadotropin (LH and FSH) secretion, leading to decreased testosterone production in males and estrogen production in females.
Leuprolide acetate 3.75 mg IM monthly or 11.25 mg IM every 3 months; for central precocious puberty, 7.5 mg IM monthly or 22.5 mg IM every 3 months.
3.75 mg intramuscularly once every 28 days.
None Documented
None Documented
Terminal elimination half-life is approximately 3 hours following subcutaneous administration; however, due to the depot formulation, the effective half-life is extended to about 1 month, driven by the slow release from the PLGA microspheres.
Terminal elimination half-life is 28-35 hours in healthy adults, allowing for a 4-week dosing interval. In patients with renal impairment, half-life is prolonged.
Renal (approximately 50% as unchanged drug and 50% as inactive metabolites); biliary/fecal excretion accounts for <5%
Renal (approximately 50% as unchanged drug and metabolites); biliary/fecal (approximately 20-30%); the remainder is metabolized.
Category C
Category C
GnRH Agonist
GnRH Agonist